AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lym
Data from two Phase I/II trials presented at American Society of Hematology ...
2017-12-13
文传商讯
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relap
81% overall response rate and 40% complete response rate by investigator ass...
2017-12-13
文传商讯
SES Launches Rapid Response Vehicle for Defence, Security and Humanitar
New addition to SES’s government services portfolio is world’s first SATCO...
2017-05-02
文传商讯
